Kinetic modelling of the role of the aldehyde dehydrogenase enzyme and the breast cancer resistance protein in drug resistance and transport

被引:1
作者
Atari, M. I. [1 ]
Chappell, M. J. [1 ]
Errington, R. J. [2 ]
Smith, P. J. [3 ]
Evans, N. D. [1 ]
机构
[1] Univ Warwick, Sch Engn, Coventry CV4 7AL, W Midlands, England
[2] Cardiff Univ, Univ Wales, Coll Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales
[3] Cardiff Univ, Univ Wales, Coll Med, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales
基金
英国生物技术与生命科学研究理事会;
关键词
Efflux pump; Drug kinetics; Topotecan; Aldehyde dehydrogenase; Structural identifiability; Parameter estimation; DNA TOPOISOMERASE-I; MULTIDRUG-RESISTANCE; STEADY-STATE; TOPOTECAN; CELLS; IDENTIFIABILITY; CAMPTOTHECINS; BCRP/ABCG2; ABCG2;
D O I
10.1016/j.cmpb.2010.06.008
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
A compartmental model for the in vitro uptake kinetics of the anti-cancer agent topotecan (TPT) has been extended from a previously published model. The extended model describes the drug activity and delivery of the pharmacologically active form to the DNA target as well as the catalysis of the aldehyde dehydrogenase (ALDH) enzyme and the elimination of drug from the cytoplasm via the efflux pump. Verification of the proposed model is achieved using scanning-laser microscopy data from live human breast cancer cells. Before estimating the unknown model parameters from the experimental in vitro data it is essential to determine parameter uniqueness (or otherwise) from this imposed output structure. This is formally performed as a structural identifiability analysis, which demonstrates that all of the unknown model parameters are uniquely determined by the output structure corresponding to the experiment. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 50 条
  • [31] Early in vitro evidence indicates that deacetylated sialic acids modulate multi-drug resistance in colon and lung cancers via breast cancer resistance protein
    Tuffour, Isaac
    Amuzu, Setor
    Bayoumi, Hala
    Surtaj, Iram
    Parrish, Colin
    Willand-Charnley, Rachel
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [32] Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance
    Zanoni, Michele
    Bravaccini, Sara
    Fabbri, Francesco
    Arienti, Chiara
    FRONTIERS IN MEDICINE, 2022, 9
  • [33] Redefine the role of D-α-Tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein, multidrug resistance protein 1, and breast cancer resistance protein mediated cancer multidrug resistance
    Chen, Jing-Yi
    Sung, Chieh-Ju
    Chen, Ssu-Chi
    Hsiang, Yi-Ping
    Hsu, Yung-Chia
    Teng, Yu-Ning
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 190
  • [34] Gastrointestinal cancer drug resistance: the role of exosomal miRNAs
    Salehi, Mahsa
    Vafadar, Asma
    Khatami, Seyyed Hossein
    Taheri-Anganeh, Mortaza
    Vakili, Omid
    Savardashtaki, Amir
    Negahdari, Babak
    Naeli, Parisa
    Behrouj, Hamid
    Ghasemi, Hassan
    Movahedpour, Ahmad
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (03) : 2421 - 2432
  • [35] Doxorubicin resistance in breast cancer: A novel role for the human protein AHNAK
    Davis, Tanja
    van Niekerk, Gustav
    Peres, Jade
    Prince, Sharon
    Loos, Ben
    Engelbrecht, Anna-Mart
    BIOCHEMICAL PHARMACOLOGY, 2018, 148 : 174 - 183
  • [36] Interaction of the breast cancer resistance protein with plant polyphenols
    Cooray, HC
    Janvilisri, T
    van Veen, HW
    Hladky, SB
    Barrand, MA
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 317 (01) : 269 - 275
  • [37] Specific Inhibitors of the Breast Cancer Resistance Protein (BCRP)
    Pick, Anne
    Klinkhammer, Werner
    Wiese, Michael
    CHEMMEDCHEM, 2010, 5 (09) : 1498 - 1505
  • [38] Epithelial-mesenchymal transition and drug resistance in breast cancer
    Huang, Jing
    Li, Hongzhong
    Ren, Guosheng
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (03) : 840 - 848
  • [39] Extracellular vesicles in breast cancer drug resistance and their clinical application
    Yu, Shentong
    Wei, Yifang
    Xu, Yuqiao
    Zhang, Yuan
    Li, Jipeng
    Zhang, Jian
    TUMOR BIOLOGY, 2016, 37 (03) : 2849 - 2861
  • [40] Pharmacological Interplay between Breast Cancer Resistance Protein and Gefitinib in Epidermal Growth Factor Receptor Signaling
    Katayama, Kazuhiro
    Shibata, Kazuhiko
    Mitsuhashi, Junko
    Noguchi, Kohji
    Sugimoto, Yoshikazu
    ANTICANCER RESEARCH, 2009, 29 (04) : 1059 - 1065